YourLawyer.com® 1-800-LAW-INFO (1-800-529-4636)
Injured by Mellaril?
In June 2005, Health Canada asked the manufacturers of Mellaril and generic thioridazine to provide evidence that the benefits of using the drug outweigh the risks. Information submitted to Health Canada failed to demonstrate the drug's safety. Health Canada received reports of three deaths between 2000 and 2005 possibly related to Mellaril, with the most recent death occurring in February 2005. Because Novartis and other manufacturers failed to make convincing safety information available, Health Canada advised the companies that sales were to end by September 30, 2005. Health Canada recommended that patients who use Mellaril seek advice from their doctors in order to be switched to alternate medications.The FDA sent a letter (http://www.fda.gov/medwatch/SAFETY/2000/mellar.htm) to physicians in July 2000 notifying them that a boxed warning was added to the label of Mellaril (thioridazine HCl). The warning states that Mellaril, like similar drugs, is associated with torsade de pointes, a type of heart arrhythmia, and sudden death. The drug prolongs the QTc interval in a dose related manner. The letter also stated that Mellaril is only indicated only for those schizophrenic patients who fail to respond to other antipsychotic drugs.
If you or a loved one took Mellaril and suffered side effects, please fill out the form at the right for a free lawsuit case evaluation by a qualified drug side effects attorney.
MellarilRSS Feed
Haldol, Compazine, Other Conventional Antipsychotics Get New Warning on Death Risk
Jun 17, 2008 | Parker Waichman Alonso LLP
Federal regulators are warning that some older antipsychotic drugs - including Haldol, Compazine, Mellaril and Thorazine - pose a risk of deaths when they are given to elderly patients suffering from dementia. The Food & Drug Administration (FDA) has asked the manufacturers of these antipsychotic drugs to add a black box warning - the agency's strongest safety notice - about this danger to their labels. The new black box warning will involve older drugs known as...
Sales Of Anti-psychotic Drug Thioridazine To Be Stopped
Sep 8, 2005 | Health Canada
Health Canada advises that manufacturer sales of thioridazine, an anti-psychotic medication used to treat schizophrenia, will be stopped by September 30, 2005. Thioridazine will continue to be dispensed by pharmacies for a transition period after that date to allow patients sufficient time to consult their health care providers and switch to an alternate medication.Health Canada has taken this action because manufacturers have failed to provide convincing safety information, requested by the...
Mellaril
Quick Facts
Mellaril Reference Guide
Generic Name
Thioridazin
Date Approved
3/15/01
Manufacturer
Novartis
Status
Removed 9/30/05
Approved Uses
Schizophrenia
Serious Side Effects
Heart rhythm changes
Death
Related Topics
Defective Drugs
Thioridazin
Date Approved
3/15/01
Manufacturer
Novartis
Status
Removed 9/30/05
Approved Uses
Schizophrenia
Serious Side Effects
Heart rhythm changes
Death
Related Topics
Defective Drugs
News Feeds
WE ALSO OFFER OUR FIRM NEWS AS RSS/XML FEEDS.
LEARN MORE ABOUT RSS